This cross-sectional study analyzes data from participants in the Alzheimer’s Biomarker Consortium–Down Syndrome study to determine which plasma biomarker combinations can accurately detect Alzheimer disease–related tau pathological brain changes in individuals with Down syndrome. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.